Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio

Eli Lilly's Q3 2026 revenue rose 39% to $24.4 billion, primarily on Mounjaro and Zepbound demand, and the company raised its 2026 revenue guidance by $5.5 billion at the midpoint to $91–92 billion. Reported EPS increased 16% to $7.22 and non-GAAP EPS increased 7% to $7.48, both including $4.57 per share of acquired IPR&D charges; updated full-year EPS guidance is $35–36. The quarter also featured multiple FDA approvals and acquisitions, while revenue included approximately $900 million of benefits, including $410 million in Jardiance milestones and favorable rebate and discount estimate adjustments.

Analysis

The key read-through is that demand is outrunning price, not that pricing power is intact: volume growth is carrying results while realized prices are falling, particularly in markets where reimbursement expands access. That can still support revenue, but it raises the risk that payer concessions and mix dilute the incremental profit from each new patient. Watch whether gross-margin improvement from mix and production costs can keep absorbing that pressure.

The headline guidance increase is less clean than it appears. Part of the year-to-date revenue benefit came from milestone and rebate/discount estimate effects, while the Jardiance milestone is nonrecurring; the call should clarify how much of the raised outlook reflects repeatable demand versus timing and accounting estimates. The large acquired-IPR&D charge obscures operating momentum in reported EPS, but acquisitions also increase execution risk and make headline EPS a poor near-term signal.

Near term, the conference call and subsequent updates on price, supply and access are the catalysts. Over 1–3 months, quarterly realized-price trends and guidance conversion matter more than volume headlines. Over 6–18 months, retatrutide’s clinical differentiation and manufacturing capacity could extend the franchise, but topline results without effect-size and safety detail are not yet a basis for assigning material value. Novo Nordisk faces a stronger competitive benchmark if retatrutide’s advantage is confirmed; payer leverage is a counterweight for the entire incretin category. The contrarian risk is that investors capitalize volume growth while underestimating price dilution and product concentration.

Key Decisions for Investors

• LLY: avoid chasing the revenue beat before the call. Consider staged exposure on weakness only if management supports the outlook with repeatable demand and clarifies that price erosion is not accelerating; reassess if realized-price pressure worsens or guidance depends materially on one-offs.
• Over the next 1–3 months, track U.S. and international realized prices, gross-margin progression, and any rebate/discount estimate reversals. A flattening of margin despite continued volume growth would falsify the operating-leverage thesis and argue for reducing exposure.
• Keep Novo Nordisk on the competitive watchlist, not as an automatic short: obtain retatrutide’s full effect-size, tolerability and discontinuation data before positioning. The topline comparison alone does not establish durable share capture.
• No standalone trade in ATAI from this release: AtaiBeckley’s acquisition is completed, but consideration, ongoing economic exposure and transaction-specific implications are not supplied. Verify those terms before treating the announcement as a catalyst for ATAI.